Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion has entered into a joint R&D agreement with Korean biotech Portrai, Inc. for target discovery and novel antibody development utilizing spatial transcriptomics platforms, with a total deal value of up to USD 87.75M (approx. KRW 125.9B).
📊 [Key Disclosure Details & Financial Summary]
- Disclosure Title: Execution of Joint R&D Agreement for Spatial Transcriptomics-Based Antibody Discovery and Subsequent Research Development (Major Management Matters)
- Counterparty: Portrai, Inc. (Korea)
- Contract / Confirmation Date: October 29, 2025
- Contract Details: Target discovery and novel drug joint R&D utilizing Portrai’s spatial transcriptomics database and analysis platform
- Contract Period: From the execution date until all payment obligations expire or early termination occurs
- Contract Values:
- Total Contract Value: Up to USD 87,750,000 (approx. KRW 125.9B / includes upfront and development milestones)
- Applied Exchange Rate: Basic rate on October 29, 2025 (USD/KRW 1,434.30)
- Disclosure Deferral: Detailed breakdown of upfront fee, milestone, and royalty conditions deferred upon counterparty request until completion of development milestones
- Investment Caution & Risk Factors:
- Conditional agreement subject to termination if research/development is halted by regulatory authorities or fails to achieve approval
- Development milestones are conditional upon achieving specific benchmarks (no penalty fees incurred if terminated early)
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Target Discovery and Joint R&D Progress Using Spatial Transcriptomics
This disclosure details Celltrion’s joint R&D agreement with Portrai to discover novel targets and develop antibody candidates using spatial transcriptomics, making it important to monitor initial target identification and research advances. Tracking R&D progress following platform integration ensures verification of project execution. Joint research achievements, milestone completions, and the eventual release of deferred disclosures can be verified through future regulatory filings or upcoming periodic reports (Quarterly, Half-Yearly, or Annual Business Reports).
📢 Disclaimer & Source Information
Source: This content was newly generated and structured based on official data submitted to the Data Analysis, Retrieval and Transfer System (DART) of the Financial Supervisory Service.
Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
